Open AccessSuccessful treatment of non-small cell lung cancer with gefitinib after erlotinib-induced severe eyelid erosion
Author(s) -
Nobuhiro Asai,
Yoshihiro Ohkuni,
Etsuro Yamaguchi,
Norihiro Kaneko
Publication year - 2015
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.139392
Subject(s) - erlotinib , gefitinib , medicine , lung cancer , epidermal growth factor receptor , tyrosine kinase inhibitor , erlotinib hydrochloride , oncology , tyrosine kinase , eyelid , adverse effect , egfr inhibitors , cancer research , pharmacology , cancer , surgery , receptor
Gefitinib and erlotinib are first-generation, small, molecular inhibitors of the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Even as these drugs have led to a paradigm shift in the treatment of advanced non-small cell lung cancer (NSCLC), drug-induced adverse effects are commonly seen. We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. As far as we had investigated, this is the first report documenting the successful cases treated with gefitinib after erlotinib-related severe eyelid erosion